Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

An examination of the dynamic changes in prostate-specific antigen occurring in a population-based cohort of men over time.

Inman BA, Zhang J, Shah ND, Denton BT.

BJU Int. 2012 Aug;110(3):375-81. doi: 10.1111/j.1464-410X.2011.10925.x. Epub 2012 Feb 7.

2.

Comparison Between the Four-kallikrein Panel and Prostate Health Index for Predicting Prostate Cancer.

Nordström T, Vickers A, Assel M, Lilja H, Grönberg H, Eklund M.

Eur Urol. 2015 Jul;68(1):139-46. doi: 10.1016/j.eururo.2014.08.010. Epub 2014 Aug 20.

3.

Impact of prostate-specific antigen on a baseline prostate cancer risk assessment including genetic risk.

Kader AK, Liss MA, Trottier G, Kim ST, Sun J, Zheng SL, Chadwick K, Lockwood G, Xu J, Fleshner NE.

Urology. 2015 Jan;85(1):165-70. doi: 10.1016/j.urology.2014.07.081.

4.

Serum prostate-specific antigen as a predictor of prostate volume in the community: the Krimpen study.

Bohnen AM, Groeneveld FP, Bosch JL.

Eur Urol. 2007 Jun;51(6):1645-52; discussion 1652-3. Epub 2007 Jan 30.

PMID:
17320271
5.

Prostate-specific antigen velocity (PSAV) risk count improves the specificity of screening for clinically significant prostate cancer.

Loeb S, Metter EJ, Kan D, Roehl KA, Catalona WJ.

BJU Int. 2012 Feb;109(4):508-13; discussion 513-4. doi: 10.1111/j.1464-410X.2011.10900.x. Epub 2012 Feb 1.

6.
7.

Improving prostate cancer detection in veterans through the development of a clinical decision rule for prostate biopsy.

Hill OT, Mason TJ, Schwartz SW, Foulis PR.

BMC Urol. 2013 Jan 29;13:6. doi: 10.1186/1471-2490-13-6.

8.

Can prostate-specific antigen and prostate-specific antigen velocity be used for prostate cancer screening in men older than 70 years?

Mouraviev V, Broadwater G, Sun L, Mayes JM, Moul JW, Polascik TJ.

Urology. 2008 Jun;71(6):1020-3. doi: 10.1016/j.urology.2007.11.016. Epub 2008 Feb 11.

PMID:
18267331
9.

Digital rectal examination is barrier to population-based prostate cancer screening.

Nagler HM, Gerber EW, Homel P, Wagner JR, Norton J, Lebovitch S, Phillips JL.

Urology. 2005 Jun;65(6):1137-40.

PMID:
15922431
10.

Can the prostate risk calculator based on Western population be applied to Asian population?

Yoon DK, Park JY, Yoon S, Park MS, Moon du G, Lee JG, Schröder FH.

Prostate. 2012 May 15;72(7):721-9. doi: 10.1002/pros.21475. Epub 2011 Aug 11.

PMID:
21837777
11.

Complexed prostate specific antigen density is better than the other PSA derivatives for detection of prostate cancer in men with total PSA between 2.5 and 20 ng/ml: results of a prospective multicenter study.

Sözen S, Eskicorapci S, Küpeli B, Irkilata L, Altinel M, Ozer G, Uygur C, Alkibay T, Ozen H.

Eur Urol. 2005 Mar;47(3):302-7. Epub 2004 Dec 1.

PMID:
15716190
12.

Predictors of prostate cancer evaluated by receiver operating characteristics partial area index: a prospective institutional study.

Gjengstø P, Paus E, Halvorsen OJ, Eide J, Akslen LA, Wentzel-Larsen T, Hoisaeter PA.

J Urol. 2005 Feb;173(2):425-8.

PMID:
15643193
13.

Prostate-specific antigen-based early detection of prostate cancer--validation of screening without rectal examination.

Schröder FH, Roobol-Bouts M, Vis AN, van der Kwast T, Kranse R.

Urology. 2001 Jan;57(1):83-90.

PMID:
11164149
14.
15.
16.

The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume.

Corcoran NM, Casey RG, Hong MK, Pedersen J, Connolly S, Peters J, Harewood L, Gleave ME, Costello AJ, Hovens CM, Goldenberg SL.

BJU Int. 2012 Jul;110(1):36-42. doi: 10.1111/j.1464-410X.2011.10681.x. Epub 2011 Nov 15.

17.

Enhanced discrimination of benign from malignant prostatic disease by selective measurements of cleaved forms of urokinase receptor in serum.

Piironen T, Haese A, Huland H, Steuber T, Christensen IJ, Brünner N, Danø K, Høyer-Hansen G, Lilja H.

Clin Chem. 2006 May;52(5):838-44. Epub 2006 Mar 16.

18.

Comparison of analysis of the different prostate-specific antigen forms in serum for detection of clinically localized prostate cancer.

Björk T, Piironen T, Pettersson K, Lövgren T, Stenman UH, Oesterling JE, Abrahamsson PA, Lilja H.

Urology. 1996 Dec;48(6):882-8.

PMID:
8973671
19.

An artificial neural network for five different assay systems of prostate-specific antigen in prostate cancer diagnostics.

Stephan C, Cammann H, Meyer HA, Müller C, Deger S, Lein M, Jung K.

BJU Int. 2008 Sep;102(7):799-805. doi: 10.1111/j.1464-410X.2008.07765.x. Epub 2008 Jun 3.

20.

Predictors of prostate cancer on repeat prostatic biopsy in men with serum total prostate-specific antigen between 4.1 and 10 ng/mL.

Okegawa T, Kinjo M, Ohta M, Miura I, Horie S, Nutahara K, Higashihara E.

Int J Urol. 2003 Apr;10(4):201-6.

Supplemental Content

Support Center